CM24 combined with Opdivo and chemotherapy showed significant survival benefits in pancreatic cancer patients with CEACAM1 biomarkers. The study reported up to a 90% reduction in risk of death in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback